We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

37 hedge funds and large institutions have $92.1M invested in NKGen Biotech, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
37
Holders Change
+37
Holders Change %
–
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
37
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$13.2M
2
HCM
Highbridge Capital Management
New York
+$11M
3
RCM
Radcliffe Capital Management
Pennsylvania
+$5.85M
4
6CM
683 Capital Management
New York
+$4.88M
5
FTCM
Fir Tree Capital Management
New York
+$4.88M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$13.1M +$13.2M +1,350,000 New
HCM
2
Highbridge Capital Management
New York
$10.9M +$11M +1,124,431 New
RCM
3
Radcliffe Capital Management
Pennsylvania
$5.81M +$5.85M +600,000 New
6CM
4
683 Capital Management
New York
$4.84M +$4.88M +500,000 New
FTCM
5
Fir Tree Capital Management
New York
$4.84M +$4.88M +500,000 New
SCC
6
Spring Creek Capital
Kansas
$4.46M +$4.49M +460,200 New
Balyasny Asset Management
7
Balyasny Asset Management
Illinois
$3.88M +$3.9M +400,000 New
Goldman Sachs
8
Goldman Sachs
New York
$3.54M +$3.56M +365,000 New
UOC
9
UBS O'Connor
Illinois
$3.4M +$3.42M +350,979 New
TCA
10
Taconic Capital Advisors
New York
$3.39M +$3.41M +350,000 New
PAMP
11
Polar Asset Management Partners
Ontario, Canada
$2.91M +$2.93M +300,000 New
AA
12
AQR Arbitrage
Connecticut
$2.79M +$2.8M +287,640 New
SCM
13
Saba Capital Management
New York
$2.57M +$2.59M +265,130 New
SCM
14
Shaolin Capital Management
Florida
$2.46M +$2.47M +253,394 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$2.45M +$2.46M +252,656 New
Bank of America
16
Bank of America
North Carolina
$2.42M +$2.44M +249,900 New
RCM
17
Rivernorth Capital Management
Florida
$1.94M +$1.95M +199,990 New
AIMCA
18
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.94M +$1.95M +200,000 New
JG
19
Jefferies Group
New York
$1.7M +$1.71M +175,000 New
ACM
20
Atalaya Capital Management
New York
$1.45M +$1.46M +150,000 New
CH
21
CVI Holdings
Delaware
$1.45M +$1.46M +150,000 New
NRCM
22
Northern Right Capital Management
Connecticut
$1.45M +$1.46M +150,000 New
OCM
23
Oaktree Capital Management
California
$1.45M +$1.46M +150,000 New
GF
24
Gabelli Funds
New York
$973K +$979K +100,396 New
SC
25
Sculptor Capital
New York
$969K +$975K +100,000 New
1
2

NKGN Hedge Fund Activity: Q3 2021 in Review

37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2021, worth a combined $92.1M.

Buyers outnumbered sellers: 37 funds opened new NKGN positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $13.2M.

  • 37 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $92.1M of NKGen Biotech, Inc. Common Stock stock for Q3 2021.
  • 37 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2021 and 0 closed out, a net change of +37 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2021 was Adage Capital Partners, an estimated $13.2M added.

Based on aggregated 13F filings for Q3 2021.